Combination therapy of glucocorticoids and proteasome inhibitors
Many disorders of the CNS change the functionality and integrity of the BBB. Glucocorticoids (GC) are being used successfully in the treatment of some disorders while their effects on others are questionable and the nature of the underlying molecular mechanisms is still a matter of debate. While glucocorticoids potently stabilize the blood brain barrier in neoplastic and inflammatory central nervous system disorders, they are however ineffective in other diseases of the CNS affecting BBB integrity.
Excessive proteasomal glucocorticoid receptor degradation has been identified as an important mechanism causing pharmacological insensitivity of brain microvascular endothelial cells to glucocorticoids in ischemic brain disorders like acute ischemic stroke. In vitro and in vivo, restoration of glucocorticoid sensitivity and effective edema reduction was achieved by inhibition of the proteasomal pathway by Bortezomib accompanied by treatment with a specific glucocorticoid.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work
Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…
New SPECT/CT technique shows impressive biomarker identification
…offers increased access for prostate cancer patients. A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more…
How 3D printers can give robots a soft touch
Soft skin coverings and touch sensors have emerged as a promising feature for robots that are both safer and more intuitive for human interaction, but they are expensive and difficult…